Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil

Abstract Background Triple-negative breast cancer (TNBC) is a heterogeneous disease that represents 10–20% of cases. The prognosis for advanced TNBC usually poor, with median overall survival approximately 18 months or less. Main text New targeted therapies such as anti-PD-L1 agents are emerging an option to treat TNBC. A panel 6 national experts active interest in convened online. Panel members had either clinical pathology experience cancer. pre-defined critical questions the management PD-L1 TNBC, and literature review was performed selected topics before online meeting. Conclusion led discussions involving multidisciplinary team comprising pathologists oncologists. meeting served discuss most relevant issues. total 10 PD-L1+ were debated presented this review. This article discusses current landscape tests Brazil.